Scientists of Far Eastern Federal University (FEFU) have suggested a risky method of anti-cancer therapy. Their review of mechanisms for molecular activation of stem cells of gliomas (most widely-spread brain tumors) was approved for publishing in the Frontiers in Cellular Neuroscience journal.
The scientists focused on the transition of cancerous stem cells from sleeping to awake mode and further to active division. Stem cells are rare cells that are responsible not only for a tumor's growth and spreading, but also for its relapsing which poses a major problem for modern therapy. A tumor may relapse soon after a surgery or chemotherapy, or it may take long time to return.
The difficulty of the therapy lies in the fact that stem cells may be influenced only in their active phase which is difficult to detect.
While certain specific cell channels are blocked in the course of the therapy, the blockage is compensated by a number of molecular links working on a different level.
This issue may be resolved with the help of differential therapy. The idea is to make the stem cells of a glioma reboot the cell cycle, i.e. to bring them into their active state and to attack them unexpectedly with chemotherapy at the moment when they're already not sleeping, but are not yet protected.
"We would like to focus on an extremely important question: whether the peculiarities and molecular mechanisms of the cells surrounding glioma stem cells affect the activation of the latter, or they are activated independently," says Alexander Kagansky.
Cancer stem cells may remain sleeping for a long time and be activated unexpectedly under the influence of an external factor, such as physical trauma or psychological stress.
Modern studies do not pay enough attention to the mechanisms of cancer stem cells activation because they are difficult to identify. They are also genetically similar to regular stem cells, although the cells of gliomas have their specific features, namely genetic peculiarities. Scientists also know that the spreading of the tumors are determined by mutations in specific proteins. However, it is still unclear how these proteins are connected to the activation of tumor stem cells.
Another cancer treatment method covered by the article (and also illustrated with glioma as an example) is associated with molecular profiling of tumor cells. The idea is that scientists should identify genetic peculiarities of tumor cells and find out its dominant gene and specific markers. To obtain such information on all required subcellular levels means to enter a new stage in the development of oncology and medicine in general.
However, for this method to be successfully developed, further studies of cancer stem cells hierarchy and the mechanisms that activate or deactivate them are required.